Feb 17, 2006
Venture Capitalizing on Avian Flu Risk
According to the latest issue of FierceBiotech, just received in the Sciencebase office, venture capitalists are hoping to invest in bird flu. Apparently, Kleiner Perkins Caufield & Byers (they always have such long company names don’t they?) is starting a US$200 million life sciences fund to focus on new therapies against avian influenza ahead of a putative global pandemic. FierceBiotech reports that biopharma and university groups are to be steered towards this area of research with BioCryst Pharmaceuticals of Birmingham, first up for funding to help it develop its antiviral Peramivir.
